---
layout: default
title: Published Cases - PPEGC
---

<div class="page-header">
  <h1>Published Cases</h1>
  <p>Browse exceptional cancer cases curated by the PPEGC scientific team</p>
</div>

<!-- Stats Bar -->
<div class="stats-bar">
  <div class="stat-box">
    <div class="stat-number">3</div>
    <div class="stat-label">Total Cases</div>
  </div>
  <div class="stat-box">
    <div class="stat-number">3</div>
    <div class="stat-label">Cancer Types</div>
  </div>
  <div class="stat-box">
    <div class="stat-number">3</div>
    <div class="stat-label">Countries</div>
  </div>
  <div class="stat-box">
    <div class="stat-number">100%</div>
    <div class="stat-label">Open Access</div>
  </div>
</div>

<!-- Filter Bar -->
<div class="filter-bar">
  <strong>Filter by:</strong>
  <button class="filter-btn active">All Cases</button>
  <button class="filter-btn">Exceptional Response</button>
  <button class="filter-btn">Resistance</button>
  <button class="filter-btn">Toxicity</button>
  <button class="filter-btn">Lung Cancer</button>
  <button class="filter-btn">Melanoma</button>
  <button class="filter-btn">Colorectal</button>
</div>

<!-- Cases Grid -->
<div class="case-grid">
  
  <!-- Case 1 -->
  <div class="case-card">
    <div class="case-header">
      <div class="case-id">PPEGC-2025-0001</div>
      <div class="case-date">Feb 15, 2025</div>
    </div>
    
    <div class="case-title">
      NSCLC with EGFR L858R+T790M: Exceptional Osimertinib Response
    </div>
    
    <div class="case-meta">
      <div class="case-meta-item">
        <span>ğŸ§¬</span> EGFR
      </div>
      <div class="case-meta-item">
        <span>ğŸ’Š</span> Osimertinib
      </div>
    </div>
    
    <div class="case-tags">
      <span class="case-tag tag-response">Exceptional Response</span>
      <span class="case-tag" style="background: #e3f2fd; color: #1565c0;">Lung Cancer</span>
    </div>
    
    <div class="case-description">
      Complete response at 8 weeks maintained >24 months. Despite extensive disease burden, patient achieved complete metabolic resolution with minimal toxicity.
    </div>
    
    <div class="case-footer">
      <div class="case-region">ğŸ‡«ğŸ‡· EUR-047</div>
      <a href="cases/PPEGC-2025-0001.html" class="btn-view">
        View Case <span>â†’</span>
      </a>
    </div>
  </div>
  
  <!-- Case 2 -->
  <div class="case-card">
    <div class="case-header">
      <div class="case-id">PPEGC-2025-0002</div>
      <div class="case-date">Feb 16, 2025</div>
    </div>
    
    <div class="case-title">
      BRAF V600E Melanoma with PTEN Loss: Primary Vemurafenib Resistance
    </div>
    
    <div class="case-meta">
      <div class="case-meta-item">
        <span>ğŸ§¬</span> BRAF, PTEN
      </div>
      <div class="case-meta-item">
        <span>ğŸ’Š</span> Vemurafenib
      </div>
    </div>
    
    <div class="case-tags">
      <span class="case-tag tag-resistance">Primary Resistance</span>
      <span class="case-tag" style="background: #fce4ec; color: #880e4f;">Melanoma</span>
    </div>
    
    <div class="case-description">
      Progressive disease despite canonical V600E mutation. Concurrent PTEN nonsense mutation detected at baseline, suggesting novel resistance mechanism.
    </div>
    
    <div class="case-footer">
      <div class="case-region">ğŸ‡ºğŸ‡¸ NAM-023</div>
      <a href="cases/PPEGC-2025-0002.html" class="btn-view">
        View Case <span>â†’</span>
      </a>
    </div>
  </div>
  
  <!-- Case 3 -->
  <div class="case-card">
    <div class="case-header">
      <div class="case-id">PPEGC-2025-0003</div>
      <div class="case-date">Feb 17, 2025</div>
    </div>
    
    <div class="case-title">
      Colorectal Cancer: Severe FOLFIRI Toxicity with UGT1A1/DPYD Variants
    </div>
    
    <div class="case-meta">
      <div class="case-meta-item">
        <span>ğŸ§¬</span> UGT1A1, DPYD
      </div>
      <div class="case-meta-item">
        <span>ğŸ’Š</span> FOLFIRI
      </div>
    </div>
    
    <div class="case-tags">
      <span class="case-tag tag-toxicity">Severe Toxicity</span>
      <span class="case-tag" style="background: #fff9c4; color: #f57f17;">Colorectal</span>
    </div>
    
    <div class="case-description">
      Grade 4 toxicity requiring ICU admission. Compound pharmacogenomic variants (*28/*28 + IVS14+1G>A) identified retrospectively, highlighting importance of pre-treatment screening.
    </div>
    
    <div class="case-footer">
      <div class="case-region">ğŸ‡¯ğŸ‡µ ASI-091</div>
      <a href="cases/PPEGC-2025-0003.html" class="btn-view">
        View Case <span>â†’</span>
      </a>
    </div>
  </div>
  
</div>

---

## Browse by Category

### Cancer Type
- [Lung Cancer](#) (1 case)
- [Melanoma](#) (1 case)
- [Colorectal Cancer](#) (1 case)

### Phenotype
- [Exceptional Response](#) (1 case)
- [Unexpected Resistance](#) (1 case)
- [Unusual Toxicity](#) (1 case)

### Gene
- [EGFR](#) (1 case)
- [BRAF](#) (1 case)
- [PTEN](#) (1 case)
- [UGT1A1](#) (1 case)
- [DPYD](#) (1 case)

---

<div style="background: #f8f9fa; padding: 40px; border-radius: 8px; text-align: center; margin: 40px 0;">
  <h2 style="color: #2E75B6; margin-top: 0;">Have an Exceptional Case?</h2>
  <p style="font-size: 1.1em; margin-bottom: 25px;">Share your observation with the international oncology community</p>
  <a href="https://redcap.link/ppegc-submit" style="display: inline-block; background: #2E75B6; color: white; padding: 15px 40px; border-radius: 8px; text-decoration: none; font-weight: bold;">Submit Your Case</a>
  <p style="margin-top: 20px; color: #666; font-size: 0.9em;">Fast review (7-15 days) â€¢ Full attribution â€¢ Open access publication</p>
</div>

---

[â† Back to Home](index.html) | [About PPEGC](ABOUT.html) | [FAQ](FAQ.html)
